Glass I, Swindlehurst C, Aitken D, McCrea W, Boyd E. Interstitial deletion of the long arm of chromosome 2 with normal levels of isocitrate dehydrogenase. J Med Genet. 1989;26:127–30.
Balasubramanian M, Smith K, Basel-Vanagaite L, Feingold M, Brock P, Gowans G, et al. Case series: 2q33. 1 microdeletion syndrome—further delineation of the phenotype. J Med Genet. 2011;48:290–8.
Zarate YA, Fish JL. SATB2‐associated syndrome: Mechanisms, phenotype, and practical recommendations. Am J Med Genet Part A. 2017;173:327–37.
Malfait F, Francomano C, Byers P, Belmont J, Berglund B, Black J, et al. The 2017 international classification of the Ehlers–Danlos syndromes. Am J Med Genet Part C: Semin Med Genet. 2017;175:8–26.
Sobey G. Ehlers–Danlos syndrome: how to diagnose and when to perform genetic tests. Arch Dis Child. 2015;100:57–61.
Leistritz D, Pepin M, Schwarze U, Byers PH. COL3A1haploinsufficiency results in a variety of Ehlers-Danlos syndrome type IV with delayed onset of complications and longer life expectancy. Genet Med. 2011;13:717–22.
Pepin MG, Schwarze U, Rice KM, Liu M, Leistritz D, Byers PH. Survival is affected by mutation type and molecular mechanism in vascular Ehlers-Danlos syndrome (EDS type IV). Genet Med. 2014;16:881–8.
Ritelli M, Dordoni C, Venturini M, Chiarelli N, Quinzani S, Traversa M, et al. Clinical and molecular characterization of 40 patients with classic Ehlers-Danlos syndrome: identification of 18 COL5A1 and 2 COL5A2 novel mutations. Orphanet J Rare Dis. 2013;12:1–19.
Ritelli M, Venturini M, Cinquina V, Chiarelli N, Colombi M. Multisystemic manifestations in a cohort of 75 classical Ehlers-Danlos syndrome patients: natural history and nosological perspectives. Orphanet J Rare Dis. 2020;15:1–18.
Martin AR, Williams E, Foulger RE, Leigh S, Daugherty LC, Niblock O, et al. PanelApp crowdsources expert knowledge to establish consensus diagnostic gene panels. Nat Genet. 2019;51:1560–1565. https://nhsgms-panelapp.genomicsengland.co.uk/panels/53/v3.0
Angwin C, Ghali N, Baker D, Brady A, Pope F, Vandersteen A, et al. Electron microscopy in the diagnosis of Ehlers–Danlos syndromes: correlation with clinical and genetic investigations. Br J Dermatol. 2020;182:698–707.
Crowther MA, Lach B, Dunmore PJ, Roach MR. Vascular collagen fibril morphology in type IV Ehlers-Danlos syndrome. Connect Tissue Res. 1991;25:209–17.
Bowen JM, Sobey GJ, Burrows NP, Colombi M, Lavallee ME, Malfait F, et al. Ehlers-Danlos syndrome, classical type. Am J Med Genet. 2017;175:27–39.
Van Buggenhout G, Van Ravenswaaij-Arts C, Mc Maas N, Thoelen R, Vogels A, Smeets D, et al. The del(2)(q32.2q33) deletion syndrome defined by clinical and molecular characterization of four patients. Eur J Med Genet. 2005;48:276–89.
Mencarelli MA, Caselli R, Pescucci C, Hayek G, Zappella M, Renieri A, et al. Clinical and molecular characterization of a patient with a 2q31.2-32.3 deletion identified by array-CGH. Am J Med Genet Part A. 2007;143A:858–65.
Prontera P, Bernardini L, Stangoni G, Capalbo A, Rogaia D, Ardisia, et al. 2q31.2q32.3 deletion syndrome: report of an adult patient. Am J Med Genet Part A. 2009;149A:706–12.
Rifai L, Port‐Lis M, Tabet A, Bailleul‐Forestier I, Benzacken B, Drunat, et al. Ectodermal dysplasia-like syndrome with mental retardation due to contiguous gene deletion: further clinical and molecular delineation of del(2q32) syndrome. Am J Med Genet Part A. 2010;152A:111–7.
Meienberg J, Rohrbach M, Neuenschwander S, Spanaus K, Giunta C, Alonso S, et al. Hemizygous deletion of COL3A1, COL5A2, and MSTN causes a complex phenotype with aortic dissection: a lesson for and from true haploinsufficiency. Eur J Hum Genet. 2010;18:1315–21.
Ferreira SI, Matoso E, Venâncio M, Saraiva J, Melo JB, et al. Critical region in 2q31.2q32.3 deletion syndrome: report of two phenotypically distinct patients, one with an additional deletion in alagille syndrome region. Mol Cytogenet. 2012;5:25–25.
Mc Cormack A, Taylor J, Gregersen N, George AM, & Love DR. Delineation of 2q32q35 deletion phenotypes: two apparent “Proximal” and “Distal” syndromes. Case Rep Genet 2013;823451.
Kempers MJ, Wessels M, Van Berendoncks A, van de Laar IM, de Leeuw N, Loeys B. Phenotype of COL3A1/COL5A2 deletion patients. Eur J Med Genet. 2022;65:104593.
Shalhub S, Black JH, Cecchi AC, Xu Z, Griswold BF, Safi HJ, et al. Molecular diagnosis in Vascular Ehlers-Danlos Syndrome predicts pattern of arterial involvement and outcomes. J Vasc Surg. 2014;60:160–9. (2014)
Frank M, Albuisson J, Ranque B, Golmard L, Mazzella J-M, Bal-Theoleyre L, et al. The type of variants at the COL3A1 gene associates with the phenotype and severity of vascular Ehlers–Danlos syndrome. Eur J Hum Genet. 2015;23:1657–64.
Demirdas S, van den Bersselaar LM, Lechner R, Bos J, Alsters SIM, Baars MJH, et al. Vascular Ehlers-Danlos Syndrome: a comprehensive natural history study in a Dutch national cohort of 142 patients. Circulation: Genom Precis Med. 2024, https://doi.org/10.1161/CIRCGEN.122.003978.
Adham S M, Zinzindohoué F, Jeunemaitre X, Frank M. Natural history and surgical management of colonic perforations in Vascular Ehlers-Danlos Syndrome: a retrospective review. Dis Colon Rectum. 2019;62:859–66. 859-866
Bowen JM, Hernandez M, Johnson DS, Green C, Kammin T, Baker D, et al. Diagnosis and management of vascular Ehlers-Danlos syndrome: experience of the UK National Diagnostic Service, Sheffield. Eur J Hum Genet. 2023;31:749–60. https://doi.org/10.1038/s41431-023-01343-7
Byers PH, Belmont J, Black J, De Backer J, Frank M, Jeunemaitre X, et al. J Med Genet Part C: Semin Med Genet, 2017;175:40–47.
Drera B, Zoppi N, Ritelli M, Barlati S, Colombi M, Tadini G, et al. Diagnosis of vascular Ehlers-Danlos syndrome in Italy: clinical findings and novel COL3A1 mutations. J Dermatol Sci. 2011;64:237–40.
Shimaoka Y, Kosho T, Wataya‐Kaneda M, Funakoshi M, Suzuki T, Hayashi S, et al. Clinical and genetic features of 20 Japanese patients with vascular-type Ehlers–Danlos syndrome. Br J Dermatol. 2010;163:704–10.
Oderich GS, Panneton JM, Bower TC, Lindor NM, Cherry KJ, Noel AA, et al. The spectrum, management and clinical outcome of Ehlers-Danlos syndrome type IV: a 30-year experience. J Vasc Surg. 2005;42:98–106.
Kuming B, Joffe L. Ehlers-Danlos syndrome associated with keratoconus-a case report. South Afr Med J. 1977;52:403–5.
Henneton P, Albuisson J, Denarié N, Mazzella J-M, Mousseaux E. Vascular Ehlers-Danlos syndrome: long-term observational study. J Am Coll Cardiol. 2019;73:1948–57.
Zarate YA, Bosanko KA, Thomas MA, Miller DT, Cusmano‐Ozog K, Martinez‐Monseny A, et al. Growth, development, and phenotypic spectrum of individuals with deletions of 2q33. 1 involving SATB2. Clin Genet. 2021;99:547–57.
Park AC, Phillips CL, Pfeiffer FM, Roenneburg DA, Kernien JF, Adams SM, et al. Homozygosity and heterozygosity for null Col5a2 alleles produce embryonic lethality and a novel classic Ehlers-Danlos Syndrome-related phenotype. Am J Pathol. 2015;185:2000–11.